Long-term survival in MIRAGE syndrome: Insights into systemic manifestations and management with review of literature
Open Access
- 1 January 2026
- journal article
- review article
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (8) , EJ25-0656-982
Abstract
MIRAGE syndrome is a multisystemic disorder with a poor prognosis, caused by gain-of-function mutations in the SAMD9 gene. To date, no comprehensive reports on the systemic manifestations and management of MIRAGE syndrome in adult survivors. Here, we present the case of a 22-year-old man long-term survivor of MIRAGE syndrome with a wide range of clinical presentations and complications. From the neonatal period, he exhibited the core features of MIRAGE syndrome: myelodysplasia, recurrent infection, growth retardation, adrenal hypoplasia, atypical external genitalia, and enteropathy. Additionally, brain imaging at 5 years of age revealed new findings, including basal ganglia and white matter lesions, calcification, infarction, and ventricular enlargement. Subsequently, proteinuria was detected at 6 years of age, which gradually progressed to end-stage renal disease. At 21 years of age, he received a living-donor kidney transplant from his father, the first transplant reported for this syndrome. Genetic analysis identified a congenital SAMD9 mutation (p.Gln1286Lys) and three acquired reversion mutations. These revision mutations mitigated his hematologic complications but did not fully restore immune function. In addition to persistent immunological and endocrine dysfunction, the patient has developed progressive neurological and metabolic abnormalities over time. Multidisciplinary management, including prophylactic intravenous immunoglobulin therapy, renal replacement therapy and transplantation, and endocrine support, was provided and may have contributed to his long-term survival. This case highlights the evolving clinical spectrum of MIRAGE syndrome and underscores the importance of careful longitudinal monitoring for patients who survive beyond early childhood.Keywords
This publication has 46 references indexed in Scilit:
- Novel SAMD9 Variant Causing MIRAGE Syndrome Treated with Subcutaneous ImmunoglobulinJournal of Clinical Immunology, 2024
- Clinical and Immunological Analyses of Ten Patients with MIRAGE SyndromeJournal of Clinical Immunology, 2021
- Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndromeCancer Genetics, 2020
- Ribosome Collisions Trigger General Stress Responses to Regulate Cell FateCell, 2020
- Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L MutationsTransplantation and Cellular Therapy, 2019
- A novel SAMD9 variant identified in patient with MIRAGE syndrome: Further defining syndromic phenotype and review of previous casesPediatric Blood & Cancer, 2019
- Somatic mosaic monosomy 7 and UPD7q in a child with MIRAGE syndrome caused by a novel SAMD9 mutationPediatric Blood & Cancer, 2018
- A novel SAMD9 mutation causing MIRAGE syndrome: An expansion and review of phenotype, dysmorphology, and natural historyAmerican Journal of Medical Genetics Part A, 2017
- Comment on: Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features of dyskeratosis congenita and IMAGe associationPediatric Blood & Cancer, 2017
- SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7Nature Genetics, 2016